Xtant Medical Holdings (XTNT) EBITDA (2010 - 2025)

Xtant Medical Holdings (XTNT) has 16 years of EBITDA data on file, last reported at $17.8 million in Q4 2025.

• On a quarterly basis, EBITDA rose 1043.36% year-over-year to $17.8 million in Q4 2025; TTM through Dec 2025 was $26.0 million, a 315.17% increase from a year earlier, with the FY2025 full-year figure at $84.3 million, up 797.97% from the prior year.
• EBITDA for Q4 2025 stood at $17.8 million, up from $2.5 million in the prior quarter.
• Over the last five years, EBITDA for XTNT reached as high as $17.8 million in Q4 2025 and fell as low as -$3.8 million in Q4 2023.
• Historically, EBITDA has averaged -$342900.0 across 5 years, with a median of -$1.6 million in 2022.
• Across the five-year window, EBITDA tumbled 36520.0% in 2022 and jumped 1043.36% in 2025, its largest moves.
• Year by year, EBITDA stood at -$1.9 million in 2021, then increased by 9.79% to -$1.7 million in 2022, then slumped by 120.77% to -$3.8 million in 2023, then surged by 50.55% to -$1.9 million in 2024, then soared by 1043.36% to $17.8 million in 2025.
• Per Business Quant data, the three most recent EBITDA figures were $17.8 million in Q4 2025, $2.5 million in Q3 2025, and $4.6 million in Q2 2025.